NRP1 and melanoma: Intriguingly, Gal-1 knock-down did not have an additive effect in PLX-resistant cells treated with EG00229 (Figure 2C, siGAL1-EG00229 red bar) and recombinant Gal-1 could not rescue cell viability upon concomitant NRP1 blockade (Figure 2C, siGAL1-EG00229 black bar); these data indicate a mechanistic role of the NRP1 receptor in mediating Gal-1 autocrine signaling in drug-resistant melanoma cells.